# UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients

> **NCT00113919** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Arkansas** · enrollment: 14 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Busulfan

## Key facts

- **NCT ID:** NCT00113919
- **Lead sponsor:** University of Arkansas
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-06
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Due to poor accrual
- **Last updated:** 2017-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00113919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00113919, "UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00113919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*